Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers.
| Main Authors: | , , , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado em: |
2001
|
| _version_ | 1826277634789605376 |
|---|---|
| author | Hugosson, J Lilja, H Lodding, P Pihl, C |
| author_facet | Hugosson, J Lilja, H Lodding, P Pihl, C |
| author_sort | Hugosson, J |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-06T23:31:51Z |
| format | Journal article |
| id | oxford-uuid:6c4e5db2-221f-4bee-80f6-62410616b1b3 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:31:51Z |
| publishDate | 2001 |
| record_format | dspace |
| spelling | oxford-uuid:6c4e5db2-221f-4bee-80f6-62410616b1b32022-03-26T19:09:57ZTumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6c4e5db2-221f-4bee-80f6-62410616b1b3EnglishSymplectic Elements at Oxford2001Hugosson, JLilja, HLodding, PPihl, C |
| spellingShingle | Hugosson, J Lilja, H Lodding, P Pihl, C Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers. |
| title | Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers. |
| title_full | Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers. |
| title_fullStr | Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers. |
| title_full_unstemmed | Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers. |
| title_short | Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers. |
| title_sort | tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers |
| work_keys_str_mv | AT hugossonj tumorvolumeisavalidsurrogateendpointfordefiningclinicallysignificantprostatecancers AT liljah tumorvolumeisavalidsurrogateendpointfordefiningclinicallysignificantprostatecancers AT loddingp tumorvolumeisavalidsurrogateendpointfordefiningclinicallysignificantprostatecancers AT pihlc tumorvolumeisavalidsurrogateendpointfordefiningclinicallysignificantprostatecancers |